$0.9011
-0.0789-8.05%
Últ. Act.: Nov 2, 5:42 PM
Marker Therapeutics (MRKR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.19 | $-0.19 | $-0.19 | $-0.40 |
| Actual | $-0.09 | $-0.16 | $-0.09 | $-0.12 |
| Surprise | +52.6% | +15.8% | +54.2% | +70.0% |
| Revenue | ||||
| Estimate | $665600 | $665600 | $649200 | $723000 |
| Actual | $0 | $0 | $1.1M | $1.2M |
| Surprise | -100.0% | -100.0% | +69.9% | +70.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.14 | $-0.19 | $-0.22 | $-0.25 |
| Revenue | ||||
| Consensus | $2.2M | $712264 | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 14, 2026 | $-0.09 | $-0.19 | 52.6 % |
| Q1 | May 15, 2026 | $-0.16 | $-0.19 | 15.8 % |
| Q4 | Mar 18, 2026 | $-0.09 | $-0.19 | 54.2 % |
| Q3 | Nov 13, 2025 | $-0.12 | $-0.40 | 70.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 14, 2026 | $0 | $665.60K | -100.0 % |
| Q1 | May 15, 2026 | $0 | $665.60K | -100.0 % |
| Q4 | Mar 18, 2026 | $1.10M | $649.20K | 69.9 % |
| Q3 | Nov 13, 2025 | $1.23M | $723.00K | 70.5 % |